MANGALAM DRUGS AND ORGANICS
|
MANGALAM DRUGS AND ORGANICS Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.80 | 12.42 | 17.67 | 5.21 | -5.07 |
| CEPS(Rs) | 7.74 | 18.89 | 23.47 | 10.41 | -0.60 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 96.00 | 95.12 | 82.63 | 65.67 | 60.44 |
| Tax Rate(%) | 42.63 | 29.12 | 29.22 | -32.00 | -39.98 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 6.86 | 10.88 | 15.08 | 7.57 | 3.74 |
| EBIT Margin(%) | 4.02 | 8.62 | 12.70 | 5.32 | 1.12 |
| Pre Tax Margin(%) | 0.59 | 6.15 | 10.27 | 2.00 | -2.22 |
| PAT Margin (%) | 0.34 | 4.36 | 7.27 | 2.64 | -3.10 |
| Cash Profit Margin (%) | 3.29 | 6.63 | 9.66 | 5.26 | -0.36 |
| Performance Ratios | |||||
| ROA(%) | 0.37 | 6.64 | 11.31 | 3.73 | -3.67 |
| ROE(%) | 0.84 | 13.97 | 23.83 | 8.27 | -8.05 |
| ROCE(%) | 6.56 | 18.34 | 28.01 | 10.66 | 1.76 |
| Asset Turnover(x) | 1.08 | 1.52 | 1.56 | 1.42 | 1.18 |
| Sales/Fixed Asset(x) | 1.60 | 2.15 | 2.09 | 1.86 | 1.61 |
| Working Capital/Sales(x) | 9.03 | 8.21 | 15.49 | 32.26 | 18.19 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.62 | 0.47 | 0.48 | 0.54 | 0.62 |
| Receivable days | 45.61 | 40.78 | 44.73 | 33.58 | 44.31 |
| Inventory Days | 124.81 | 71.08 | 58.56 | 80.60 | 94.20 |
| Payable days | 110.40 | 58.29 | 72.42 | 83.15 | 83.21 |
| Valuation Parameters | |||||
| PER(x) | 121.95 | 8.28 | 5.62 | 5.82 | - |
| PCE(x) | 12.63 | 5.44 | 4.24 | 2.92 | -92.64 |
| Price/Book(x) | 1.02 | 1.08 | 1.20 | 0.46 | 0.91 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.61 | 0.53 | 0.57 | 0.34 | 0.65 |
| EV/Core EBITDA(x) | 8.74 | 4.88 | 3.80 | 3.88 | 14.88 |
| EV/EBIT(x) | 15.15 | 6.16 | 4.52 | 5.79 | 51.13 |
| EV/CE(x) | 0.63 | 0.73 | 0.84 | 0.42 | 0.70 |
| M Cap / Sales | 0.42 | 0.36 | 0.41 | 0.17 | 0.38 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -17.47 | 17.25 | 36.25 | 24.07 | -18.54 |
| Core EBITDA Growth(%) | -47.19 | -15.30 | 133.25 | 148.80 | -79.04 |
| EBIT Growth(%) | -61.52 | -20.37 | 193.25 | 472.52 | -92.93 |
| PAT Growth(%) | -93.54 | -29.72 | 238.94 | 202.76 | -140.38 |
| EPS Growth(%) | -93.54 | -29.72 | 238.94 | 202.76 | -140.38 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.49 | 0.52 | 0.49 | 0.48 | 0.66 |
| Current Ratio(x) | 1.25 | 1.42 | 1.23 | 1.09 | 1.16 |
| Quick Ratio(x) | 0.42 | 0.52 | 0.69 | 0.50 | 0.35 |
| Interest Cover(x) | 1.17 | 3.48 | 5.24 | 1.60 | 0.34 |
| Total Debt/Mcap(x) | 0.48 | 0.48 | 0.41 | 1.04 | 0.72 |
Compare Financial Ratios of peers of MANGALAM DRUGS AND ORGANICS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANGALAM DRUGS AND ORGANICS | ₹157.5 Cr | -0.4% | -21.3% | -8.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,311.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹92,794.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
MANGALAM DRUGS AND ORGANICS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANGALAM DRUGS AND ORGANICS | -0.4% |
-21.3% |
-8.1% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
